Vascepa is a prescription medication used to treat high triglyceride levels in the blood. The active ingredient in Vascepa is icosapent ethyl. According to the drug patent watch website [1], the patent for Vascepa will expire in 2030. This means that until 2030, Amarin, the manufacturer of Vascepa, has the exclusive right to produce and sell the medication. After that, other companies will be able to produce and sell generic versions of the drug, which may lead to a decrease in price.

However, the price of Vascepa may still increase without discounts before the patent expires. According to the Vascepa website [2], the medication is currently priced at $280 per month. The website also offers a savings program for eligible patients to reduce the cost of Vascepa to as low as $9 per month [3]. This suggests that the price of Vascepa may be higher without discounts.

In conclusion, the patent for Vascepa will expire in 2030, which may lead to a decrease in price due to generic competition. However, the price of Vascepa may still increase without discounts before the patent expires. Patients who are prescribed Vascepa may be eligible for discounts through the Vascepa savings program. [1][2][3]

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.vascepa.com/getting-started/vascepa-savings/
[3] https://vascepa.copaysavingsprogram.com/